2012 in review - part I: the year's new drugs & biologics.
Thirty-seven new launches are considered in the first part of this annual review article, including 36 drugs and biologics that reached their first markets worldwide in 2012 and one additional drug that was launched at the end of December 2011. In addition, 26 significant new line extensions (new indications, new formulations and new combinations of existing drugs) that were launched for the first time in 2012 are discussed in this review. Also included are new drugs and biologics and new line extensions that were approved for the first time between January and December 2012, although they were not launched before the end of the year.
Thomson Reuters, Barcelona, Spain. ann.graul@thomsonreuters.com
A I
AI
Graul
B
B
Lupone
E
E
Cruces
M
M
Stringer
D000818:Animals; D001688:Biological Products / Q000737:chemistry / Q000627:therapeutic use*; D002626:Chemistry, Pharmaceutical; D017277:Drug Approval; D004338:Drug Combinations; D055808:Drug Discovery; D004358:Drug Therapy; D006801:Humans; D004364:Pharmaceutical Preparations / Q000737:chemistry
D001688:Biological Products; D004338:Drug Combinations; D004364:Pharmaceutical Preparations